Why Verve Therapeutics Stock Crushed It This Week
Verve Therapeutics (NASDAQ: VERV), a clinical-stage gene-editing company focusing on cardiovascular disease, saw its shares race higher this week by a healthy 17.1%, according to data from S&P Global Intelligence. The biotech's stock jumped this week for three key reasons:
Verve's shares have risen by an astounding 150% since July 1, 2022. As a result, the clinical-stage biotech now sports an eye-catching $2.35 billion market capitalization.
That's an exceptionally strong sign that Wall Street is a true believer in Verve's novel gene-editing platform. Most clinical-stage biotechs, after all, have lost a staggering amount of value this year, with scores of former mid-cap companies shrinking into small-cap entities in 2022.
Source Fool.com
